We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Thermo and Fisher Merge, Creating Lab-Equipment Giant

By HospiMedica staff writers
Posted on 15 May 2006
Thermo Electron Corp. More...
(Waltham, MA, USA) and Fisher Scientific International Inc. (Hampton, NH, USA), have announced that the boards of both companies have approved an agreement to combine the two companies in a tax-free, stock-for-stock transforming merger that will create the world's leading provider of fully integrated, end-to-end solutions in the life, laboratory, and health sciences industry.

Under the terms of the agreement, Fisher shareholders will receive two shares of Thermo common stock for each share of Fisher common stock they own. Based on Thermo's closing price of $39.45 per share on May 5, 2006, this represents a value of $78.90 per Fisher share, or an aggregate equity value of $10.6 billion. Upon completion of the transaction, Thermo's shareholders will own about 39% of the combined company, while Fisher shareholders will own around 61%. The transaction, expected to close in the fourth quarter of 2006, will be treated as a reverse merger, with Thermo as the acquirer.

This new provider of laboratory products and services in the life, laboratory, and health sciences industry will be called Thermo Fisher Scientific Inc. The company will have its headquarters in Waltham (MA, USA) and is expected to have revenues of more than U.S.$9 billion in 2007. The two firms have complementary technology leadership in instrumentation, life-science consumables, software, and services. Thermo Fisher Scientific will have an industry-leading global sales and service organization, with nearly 7,500 professionals serving its customers worldwide.

The current president and chief executive officer of Thermo, Marijn E. Dekkers, will become president and CEO of the combined company, while Paul M. Meister, vice chairman of Fisher's board, will become chairman of the board of the combined company. Paul M. Montrone, chairman and CEO of Fisher, will be stepping aside in support of the new management team but will remain as an advisor to the company, concentrating on launching new business opportunities.

"This combination brings together two well-respected industry leaders in the life, laboratory, and health sciences marketplace to create a company that has the breadth, global reach, and operational expertise to drive significant value for shareholders, customers, and employees,” said Mr. Dekkers. "Both Thermo and Fisher have strong track records of acquisition success and margin expansion. By combining our companies' complementary world-class product and service offerings with Fisher's unparalleled customer access, we expect to accelerate growth by further penetrating our vast customer base.”

"This is a great transaction that provides Fisher shareholders with enhanced value both today and over the long term,” noted Mr. Meister. "The upside potential we see as a result of our combination is compelling. By leveraging the operating expertise at both companies, we anticipate realizing the strategic and financial benefits of this transaction quickly and efficiently.”



Related Links:
Thermo Electron
Fisher Scientific

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Pediatric Mask
Respire SOFT
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.